StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report released on Tuesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Down 2.6 %
EVOK stock opened at $0.48 on Tuesday. The firm has a 50-day moving average of $0.52 and a two-hundred day moving average of $0.58. Evoke Pharma has a 12 month low of $0.40 and a 12 month high of $1.68. The company has a market cap of $4.15 million, a price-to-earnings ratio of -0.26 and a beta of 0.38.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share for the quarter. Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%. The firm had revenue of $1.74 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- What Are the FAANG Stocks and Are They Good Investments?
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- What Investors Need to Know to Beat the Market
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
